Feed AMBIQ
Summary
51 / 100 · Bulios Score
Valuation 100Growth 100Profitability 41Quality 19Debt 23Stability 12
What speaks for it
- Revenue grew by 58% a year over the last 3 years.
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 4.7 years of operating profit.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (BRL)
20202021202220232024
Diluted EPS (BRL)
20202021202220232024
Revenue grew by 58% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of R$ 1.99M.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments R$ 359.2M
Debt R$ 3.44B
Free cash flow over 12 months R$ 286.6M
Repaying all its debt would take 12.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
The company reports no revenue by product.
By region
- BRAZIL 49%
- North America 44%
- Europe 6.6%
BRAZIL brings in 49% of revenue.
Segments in detail